PEPG
PepGen Inc.
$1.76
-1.68%
2026-05-08
About PepGen Inc.
PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatment of myotonic dystrophy type 1. It is also involved in FREEDOM-OLE, an open label expansion study. The company was founded in 2018 and is based in Boston, Massachusetts.
Key Fundamentals
Forward P/E
-1.54
EPS (TTM)
$-2.12
ROE
-67.4%
Profit Margin
0.0%
Debt/Equity
11.53
Price/Book
0.84
Beta
2.01
Market Cap
$123.8M
Avg Volume (10D)
946K
Recent Breakout Signals
No recent breakout signals detected for PEPG.
Recent Price Range (60 Days)
60D High
$7.14
60D Low
$1.32
Avg Volume
1.4M
Latest Close
$1.76
Get breakout alerts for PEPG
Sign up for Breakout Scanner to receive daily notifications when PEPG triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial. No card required.
PepGen Inc. (PEPG) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors PEPG daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. PEPG operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.